High-flow Oxygen for Vaso-occlusive Pain Crisis

NCT03976180 | Recruiting

• 1 other identifier: P180303J
• Study Type: interventional
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD. Currently, there is no safe and effective treatment to abort VOC or prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a very limited number of patients (\<30). The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one of the most potent and readily alterable. Current guidelines recommend oxygen therapy in patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients at risk of secondary ACS because they may experience acute desaturation. In contrast, various case series suggest a potential beneficial role of intensified oxygen therapy targeting hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the latter is difficult to implement in routine clinical practice. A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to 100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60 L/min (which generates positive airway pressure and dead space flushing, that may prevent evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In patients with acute respiratory failure, HFNO has been shown to improve patient's comfort, oxygenation, and survival as compared to standard oxygen or non-invasive ventilation. The aim of the present study is to test the efficacy and safety of HFNO for the management of VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage (MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in hospital wards.

Conditions

Sickle Cell Disease

Keywords

Sickle Cell Disease; vaso-occlusive pain crisis; HFNO; ACS

Outcome Measures

Primary Outcomes (3)

• Rate of cardiac and neurologic related events (Pilot Stage)

  This endpoint will be assessed at the end of the "pilot stage" and throughout the entire study for cumulative safety information. Research arms will only continue to recruitment in the next stage if they have been shown to be both safe (\<5 cardiac or neurologic related events, in the arm during the pilot phase as defined by one of the following: acute coronary syndrome, acute ischemic stroke, or seizure) and feasible (\<8 definitive discontinuations before day-2 due to patient's intolerance), although patient data from all patients and all stages will be included in the final analyses.

  At the end end of the "pilot stage" and up to 28 days

• Rate of vaso-occlusive pain crisis (VOC) resolution without complication (Activity stage)

  VOC will be considered terminated when at least 3 of the following 4 criteria are met at two consecutive assessments: i) absence of fever for 8 hours; ii) absence of pain progression and no requirement of intravenous infusion of opioid analgesics for the last 8 hours; iii) the patient is able to walk or move without pain; iv) absence of spontaneous pain with a CPS (categorical pain score) of 1 or less

  Day 5

• Rate of secondary acute chest syndrome (ACS)(Efficacy Stage)

  Defined as the proportion of patients with secondary ACS during the 14 days following randomization. Secondary ACS is defined as the combination after randomization of a clinical sign \[chest pain or auscultatory abnormality (crepitants and/or bronchial breathing)\] with a new pulmonary infiltrate (on chest film, thoracic scan, or lung ultrasound).

  Day 14

Secondary Outcomes (12)

• Volume of transfused red blood cells and volume of exsanguinated blood

  Between day-1 (randomization) and day-14

• Pain intensity evaluated by categorical pain score

  Between day-1 (randomization) and day-14

• Pain intensity evaluated by visual analogue scale

  Between day-1 (randomization) and day-14

• VOC duration

  Day-14

• VOC-free days

  Day-14

Study Arms (4)

standard low-flow oxygen

ACTIVE COMPARATOR

In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;

Device: Stadard low-flow oxygen

HFNO with low FiO2 (21%-30%)

EXPERIMENTAL

HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;

Device: HFNO with low FiO2 (21%-30%)

HFNO with intermediate FiO2 (50%)

EXPERIMENTAL

HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia

Device: HFNO with intermediate FiO2 (50%)

HFNO with high FiO2 (100%)

EXPERIMENTAL

HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia

Device: HFNO with high FiO2 (100%)

Interventions

Stadard low-flow oxygen DEVICE

In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care

Also known as: Control group

standard low-flow oxygen

HFNO with low FiO2 (21%-30%) DEVICE

HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function

Also known as: Intervention group

HFNO with low FiO2 (21%-30%)

HFNO with intermediate FiO2 (50%) DEVICE

In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia

Also known as: Intervention group

HFNO with intermediate FiO2 (50%)

HFNO with high FiO2 (100%) DEVICE

In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia

Also known as: Intervention group

HFNO with high FiO2 (100%)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years;
• Patient with major sickle cell disease syndrome (SS, SC, Sβ0 or Sβ+);
• VOC as defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and/or pelvis, that requires opioids and is not attributable to other causes;
• Intermediate-to-high risk for secondary ACS derived from the PRESEV score (Bartolucci et al, EBioMedicine 2016) as follows: a reticulocyte count \>216 G/L OR at least two of the followings : i) spine and/or pelvis CPS \>1; ii) leucocyte count \>11G/L; iii) hemoglobin ≤ 9 g/dL; in case of long-term treatment by hydroxyurea, only one of the above mentioned criteria will be needed, given its effects on hemoglobin, leucocyte and reticulocytes counts;
• Informed consent;
• Patient affiliated to social security

You may not qualify if:

• Known cerebral vasculopathy or past medical history of stroke, due to Moya Moya or persisting visible macrovessel stenosis/occlusion;
• Known ischemic heart disease or typical chest angina;
• Patient who is currently enrolled in other investigational drug study;
• Known legal incapacity,
• Prisoners or subjects who are involuntarily incarcerated
• Anatomical factors precluding placement of a nasal cannula

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Fisher and Paykel Healthcare: collaborator
• Orkyn': collaborator

Study Sites (1)

Henri Mondor

Créteil, 94000, France

RECRUITING

Related Publications (1)

• Mekontso Dessap A, Habibi A, Guillaud C, Kassasseya C, Larrat C, Agbakou M, Tchoubou T, Candille C, Carpentier B, Landais M, Arlet JB, Fartoukh M, Desclaux A, Masseau A, Oziel J, Bouharaoua S, Affo C, Viglino D, Boukari L, Martin LE, Ngo S, Anguel N, Chantalat C, Bourgarit-Durand A, Genty I, Makowski C, Guillet S, Melica G, Lionnet F, Le Jeune S, Joseph L, Lanternier F, Cougoul P, Bertchansky I, Boue Y, Bartolucci P, Gendreau S, Audureau E. High flow oxygen for vaso-occlusive crisis: a multicentre, prospective, randomised, multi-arm, multi-stage clinical trial (OSONE). BMJ Open. 2025 Sep 17;15(9):e104564. doi: 10.1136/bmjopen-2025-104564.

  PMID: 40967654 DERIVED

MeSH Terms

Conditions

Anemia, Sickle Cell

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Study Officials

• Armand Mekontso

  Assistance Publique - Hôpitaux de Paris

  STUDY CHAIR

Central Study Contacts

Armand Mekontso, MD, PhD

CONTACT

+33 (1) 49 81 23 94; armand.dessap@aphp.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a comparative randomized controlled superiority open-label multi-arm multi-stage (MAMS) trial. The study will use a multi-arm multi-stage (MAMS) trial design with three stages and four arms (one control arm and three intervention arms). * "Pilot" stage: a formal safety/feasibility testing. Research arms will only continue to recruitment in the next stage if they have been shown to be both safe and feasible, although patient data from all patients and all stages will be included in the final analyses. * "Activity" stage: an interim comparison of activity using the rate of VOC resolution without complication at day-5 as primary endpoint. At the end of this stage, an interim analysis will be used in order to select the most promising experimental treatment and compare it to control in the subsequent stage ("pick the winner" strategy). * "Efficacy" stage: final comparison with secondary ACS at day-14 as the primary endpoint.

Study Record Dates

• First Submitted: May 24, 2019
• First Posted: June 5, 2019
• Study Start: April 27, 2020
• Primary Completion: November 27, 2025
• Study Completion: November 27, 2025
• Last Updated: July 28, 2025

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)